{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:59:40Z","timestamp":1793743180658,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1866-2","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T13:03:08Z","timestamp":1554469388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":305,"title":["Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study"],"prefix":"10.1186","volume":"21","author":[{"given":"J\u00fcrgen","family":"Wollenhaupt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Silverfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketti","family":"Terry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshika","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Mojcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"DeMasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Strengholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Lazariciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"1866_CR1","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316\u201322.","journal-title":"Ann Rheum Dis"},{"key":"1866_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/art.33383","volume":"64","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617\u201329.","journal-title":"Arthritis Rheum"},{"key":"1866_CR3","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895\u2013905.","journal-title":"Arthritis Rheum"},{"key":"1866_CR4","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970\u201381.","journal-title":"Arthritis Rheum"},{"key":"1866_CR5","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63:1150\u20138.","DOI":"10.1002\/acr.20494"},{"key":"1866_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14397595.2014.995875","volume":"25","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25:514\u201321.","journal-title":"Mod Rheumatol"},{"key":"1866_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451\u201360.","journal-title":"Lancet."},{"key":"1866_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457\u201368.","journal-title":"Lancet."},{"key":"1866_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med"},{"key":"1866_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li Z-G, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253\u201361.","journal-title":"Ann Intern Med"},{"key":"1866_CR11","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377\u201386.","journal-title":"N Engl J Med"},{"key":"1866_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D Heijde van der","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559\u201370.","journal-title":"Arthritis Rheum"},{"key":"1866_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Vollenhoven van","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508\u201319.","journal-title":"N Engl J Med"},{"key":"1866_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41:837\u201352.","journal-title":"J Rheumatol"},{"key":"1866_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","volume":"18","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34.","journal-title":"Arthritis Res Ther"},{"key":"1866_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/art.39972","volume":"69","author":"J Wollenhaupt","year":"2017","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, Terry K, Kwok K, Strengholt S, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years. Arthritis Rheumatol. 2017;69:683\u20134 abstract 522.","journal-title":"Arthritis Rheumatol."},{"key":"1866_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000491","volume":"3","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Wollenhaupt J, Takiya L, Maniccia A, Kwok K, Wang L, et al. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open. 2017;3:e000491.","journal-title":"RMD Open"},{"key":"1866_CR18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253\u201362.","journal-title":"Ann Rheum Dis"},{"key":"1866_CR19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1133\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1866_CR20","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/art.38687","volume":"66","author":"R Alten","year":"2014","unstructured":"Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol. 2014;66:1987\u201397.","journal-title":"Arthritis Rheumatol."},{"key":"1866_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1866_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"MH Schiff","year":"2006","unstructured":"Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889\u201394.","journal-title":"Ann Rheum Dis"},{"key":"1866_CR23","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1002\/art.39761","volume":"68","author":"F Xie","year":"2016","unstructured":"Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68:2612\u20137.","journal-title":"Arthritis Rheumatol."},{"key":"1866_CR24","first-page":"52","volume":"69","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Kremer J, Cohen S, Curtis JR, Charles-Schoeman C, Loftus EV, et al. Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programs. Arthritis Rheumatol. 2017;69:52\u20135 abstract 16L.","journal-title":"Arthritis Rheumatol"},{"key":"1866_CR25","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.22039","volume":"65","author":"SC Kim","year":"2013","unstructured":"Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65:1600\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1866_CR26","doi-asserted-by":"crossref","unstructured":"Ogdie A, Kay McGill N, Shin DB, Takeshita J, Jon Love T, Noe MH, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J. 2018;39:3608\u201314.","DOI":"10.1093\/eurheartj\/ehx145"},{"key":"1866_CR27","first-page":"2188","volume":"54","author":"DE Furst","year":"2015","unstructured":"Furst DE, Kavanaugh A, Florentinus S, Kupper H, Karunaratne M, Birbara CA. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Rheumatology (Oxford). 2015;54:2188\u201397.","journal-title":"Rheumatology (Oxford)"},{"key":"1866_CR28","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3899\/jrheum.170344","volume":"45","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, et al. Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial. J Rheumatol. 2018;45:1085\u201392.","journal-title":"J Rheumatol"},{"key":"1866_CR29","doi-asserted-by":"publisher","first-page":"abstract 962","DOI":"10.1002\/art.40580","volume":"70","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Smolen JS, Takeuchi T, Rooney TP, Dickson CL, Yang X-Y, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 6 years: an updated integrated safety analysis. Arthritis Rheumatol. 2018;70:abstract 962.","journal-title":"Arthritis Rheumatol."},{"key":"1866_CR30","first-page":"abstract 2815","volume":"70","author":"M Weinblatt","year":"2018","unstructured":"Weinblatt M, Taylor P, Burmester G, Saifan C, Walls C, Issa M, et al. Cardiovascular safety - update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials. Arthritis Rheumatol. 2018;70:abstract 2815.","journal-title":"Arthritis Rheumatol."},{"key":"1866_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/annrheumdis-2015-209055","volume":"76","author":"V Strand","year":"2017","unstructured":"Strand V, Ahadieh S, DeMasi R, Krishnaswami S, Geier J, Menon S, et al. Meta-analysis of serious infections with baricitinib, tofacitinib and biologic DMARDs in rheumatoid arthritis. Ann Rheum Dis. 2017;76:284 abstract THU0211.","journal-title":"Ann Rheum Dis"},{"key":"1866_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1136\/annrheumdis-2015-209064","volume":"76","author":"JJ Gomez-Reino","year":"2017","unstructured":"Gomez-Reino JJ, Checchio T, Geier J, Boy M, Ahadieh S, Menon S, et al. Systematic review and meta-analysis of malignancies, excluding non-melanoma skin cancer, in patients with rheumatoid arthritis treated with tofacitinib or biologic disease-modifying antirheumatic drugs. Ann Rheum Dis. 2017;76:277 abstract THU0196.","journal-title":"Ann Rheum Dis"},{"key":"1866_CR33","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.clinthera.2016.11.004","volume":"38","author":"MC Vieira","year":"2016","unstructured":"Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. Clin Ther. 2016;38:2628\u201341.","journal-title":"Clin Ther"},{"key":"1866_CR34","doi-asserted-by":"publisher","unstructured":"van Vollenhoven R, Lee EB, Strengholt S, Mojcik C, Valdez H, Krishnaswami S, et al. Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis Rheumatol. 2018. https:\/\/doi.org\/10.1002\/art.40780 .","DOI":"10.1002\/art.40780"},{"key":"1866_CR35","unstructured":"European Medicines Agency. Xeljanz (tofacitinib citrate) - summary of product characteristics. 2017. https:\/\/www.medicines.org.uk\/emc\/medicine\/33167 . Accessed 15 Mar 2019."},{"key":"1866_CR36","unstructured":"Pfizer Inc. XELJANZ prescribing information. 2012. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959 . Accessed 15 Mar 2019."},{"key":"1866_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40744-018-0097-3","volume":"5","author":"S Cohen","year":"2018","unstructured":"Cohen S, Curtis JR, DeMasi R, Chen Y, Fan H, Soonasra A, et al. Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol Ther. 2018;5:283\u201391.","journal-title":"Rheumatol Ther"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1866-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1866-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1866-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T17:04:47Z","timestamp":1721149487000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1866-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1866"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1866-2","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]},"assertion":[{"value":"8 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, the Declaration of Helsinki, and the Good Clinical Practice Guidelines, along with applicable local regulatory requirements and laws. The study protocol was approved by the Institutional Review Boards and\/or Independent Ethics Committee at each study center. All patients provided written, informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JW and SC are consultants for, and have received speaker fees and honoraria from, Pfizer Inc. EBL is a consultant for Pfizer Inc and has received grant\/research support from Green Cross Corporation and Hammi Pharm. JRC has received grant\/research support and consultant fees from Pfizer Inc. JS has received grant\/research support and speaker fees from Pfizer Inc. KT, KS, CM, RD, SS, KW, and LW are employees of, and hold shares in, Pfizer Inc. IL is an employee of IQVIA and a consultant for Pfizer Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"89"}}